Ken H. Herrmann

Oberdürrbacher Str. 6
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 741 publications

Radioligand Therapy of the Prostate - the Sky Is the Limit?

Radioligand Therapy of the Prostate - the Sky Is the Limit?

Journal: European urology focus

Published: July 27, 2026

Update to "Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy".

Update to "Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy".

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 16, 2026

Done EAZY: An Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer Therapeutics.

Done EAZY: An Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer Therapeutics.

Journal: Molecular pharmaceutics

Published: June 29, 2026

The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and 177Lu-PSMA Therapy Between Centers in Brazil and Europe.

The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and 177Lu-PSMA Therapy Between Centers in Brazil and Europe.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 19, 2026

FDG PET Hybrid Imaging.

FDG PET Hybrid Imaging.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

Published: May 21, 2026

ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT.

ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT.

Journal: European urology focus

Published: May 11, 2026

CAIX and CD70 Theranostics in Clear Cell Renal Cell Carcinoma: Navigating the Promise and Perils.

CAIX and CD70 Theranostics in Clear Cell Renal Cell Carcinoma: Navigating the Promise and Perils.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 22, 2026

Diagnostic Potential of Apparent Diffusion Coefficient-Based Lymph Node Classification in Breast Cancer Patients Undergoing [18F]FDG-PET/MRI.

Diagnostic Potential of Apparent Diffusion Coefficient-Based Lymph Node Classification in Breast Cancer Patients Undergoing [18F]FDG-PET/MRI.

Journal: Diagnostics (Basel, Switzerland)

Published: April 19, 2026

From Anatomy to Theranostics: Toni Choueiri Talks with Ken Herrmann About the Evolution of Genitourinary Oncology.

From Anatomy to Theranostics: Toni Choueiri Talks with Ken Herrmann About the Evolution of Genitourinary Oncology.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 09, 2026

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

Journal: European urology

Published: March 23, 2026

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 23, 2026

CXCR4-Targeted Molecular Imaging in Hematology and Oncology.

CXCR4-Targeted Molecular Imaging in Hematology and Oncology.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 22, 2026

Showing 1-12 of 741

Last Updated: 09/26/2026